About HEC

Close 80 Billion

Total assets

2

Listed Companies

Close 30000

Existing staff

50000

Laboratory

1700 People

+

R & D team

3500 Item

+

Patents

Company Profile

HEC is a high-tech large-scale joint-stock enterprise full of hope, focusing on industry and building a century-old foundation.

HEC is a high-tech large-scale joint-stock enterprise full of hope, focusing on industry and building a century-old foundation. It has more than 20,000 employees; it is mainly engaged in three major industries: "electronic new materials", "biomedicine" and "health and wellness". Now there are seven bases, located in Dongguan in Guangdong, Shaoguan in Guangdong, Yichang in Hubei, Dongyang in Zhejiang, Ulanchap in Inner Mongolia, Zunyi in Guizhou, and Nyingchi in Tibet. It has two listed companies: HEC (600676.SH) and HEC Pharmaceutical (01558.HK).

Learn more →

Development Path

The company was established in 1997

Learn more →

Enterprise Honor

More than 3,500 patents have been applied, including more than 1,500 foreign patents

 
Learn more →

Social Responsibility

HEC Group has made accumulative donations worth over 200 million yuan to the field of social welfare and charity

 
Learn more →

Staff Corner

More than 20,000 employees


Learn more →
  • New Electronic Materials

    New Electronic Materials

  • Biomedicine Industry

    Biomedicine Industry

  • Health And Wellness

    Health And Wellness

New Electronic Materials

New electronic materials - The new electronic material industry already owns an A-share listed company HEC (600673.SH); it develops core industries around the capacitor industry chain and battery material industry clusters, and has created four major industry clusters: electronic component, high-end aluminum foil, new chemical material, and new energy material. Relying on the complete industry chain and technological innovation advantages, it actively responds to the national "double carbon" policy, closely focuses on market demand, continuously improves the industrial layout, and strives to build an internationally advanced new energy material platform company within 5-8 years!

  • 東陽(yáng)光科
  • 東陽(yáng)光科
Learn mode →

Biomedicine Industry

Biomedicine industry- The biomedical industry mainly includes Sunshine Lake Pharma Co., Ltd. and HEC Pharm Co., Ltd. two business systems. Sunshine Lake Pharma Co., Ltd. includes HEC Pharmaceutical Research Institute, domestic preparation business ("HEC Changjiang Pharmaceutical", which has been listed in Hong Kong stock market) and pharmaceutical business for foreign markets; HEC Pharm Co., Ltd. is mainly engaged in bio-fermentation API.

  • 東陽(yáng)光藥
  • 東陽(yáng)光藥
Learn mode →

Health And Wellness

Health and wellness - HEC Health has a research institute with more than 200 high-end R&D talents, and has built an industrialization base mainly in Yichang, Hubei, supplemented by Shaoguan, Guangdong and Nyingchi, Tibet. In the future, the research and development and production base of Cordyceps sinensis deep processing products will be built in Zhuhai Hengqin and Dongyang, Zhejiang. Adhering to the concepts of safety, health, ecology and high technology, HEC will build a large-scale health industry dominated by Cordyceps sinensis, and continue to develop and innovate ecologically bred Cordyceps sinensis and its deep-processed products, health food, health care products, cosmetics and other large-scale health products cluster.

  • 東陽(yáng)光健
  • 東陽(yáng)光健
Learn mode →

R & D Center

In 2005, HEC established the General Research Institute, which consists of three branches: the Pharmaceutical Research Institute, the Great Health Research Institute and the New Energy Research Institute. Through 17 years of unremitting efforts, it has possessed continuous and systematic research and development capabilities. The research and development concept is occidentalized, the scientific research talents are globalized, and the research and development and testing equipment are first-class.

Learn more →

R & D Team

The institute has more than 20 foreign and returnee experts, more than 100 doctors, more than 1,000 masters, more than 1,700 R&D personnel, and has first-class medicinal chemistry capabilities, thus forming a unique R&D model of "domestic elite-led, returnee expert guidance, overseas consultant guidance”. 

Learn more →

R & D Results

The institute has applied for more than 3,500 patents, and its foreign patents are more than 1,500; the total number of pharmaceutical patents, compound patents, compound PCT patents, patent application growth rate and patent quality applied by HEC drugs each year rank in the forefront of China.

Learn more →

HEC Trends

The work summary and deployment and commendation conference of HEC Group for 2023-2024 was successfully held

On March 28-29, the work summary and deployment and commendation conference of HEC Group for 2023-2024 was successfully held in Shenzhen, Guangdong. With the theme of "Strategic focus on revitalizing the main business,

2024-04-12

Debut of HEC Fresh Cordyceps At The 2023 BFA An Amazing Work Captured World Attention And Drawn Accolades From All Society

From October 29th to 31st, the second conference of the BFA (Boao Forum for Asia) Global Economic Development and Security Forum (hereinafter referred to as the "Economic and Security Conference") concluded successfully in Changsha, Hunan. This Economic and Security Conference, with the theme of "Global Development and Shared Security", held over 30 activities including sub-forums, exhibitions, and others, focusing on digital economy, supply chain, food, energy, financial security and other topics, attracted over 2,500 participants including domestic and foreign political leaders, representatives from top 500 & listed companies and well-known expert representatives, and contributed Boao wisdom.

2023-11-02

The Biopharmaceutical Industry Management Conference of HEC Group Was Successfully Held in Hubei

From September 4 to 5, 2023, the Biopharmaceutical Industry Management Conference of HEC Group was successfully held in Wuhan, Hubei. Group chairman Zhang Yushuai, rotating chairman of the board of directors Tang Xinfa, group directors Lu Yuxin, Zhu Yingwei, Zhang Hongwei, and Deng Xinhua, group supervisors Hu Zhidong, Zhou Lin, and Wei Cailiang, as well as more than 80 heads of R&D, production, sales, functional and other departments in biopharmaceutical industry attended this conference.

2023-09-06